{"output": [["Ben Hirschler", "PERSON", "Write", "Reuters", "ORG"], ["Celgene", "COMP", "Agree_To", "Impact Biomedicines", "COMP"], ["Novo Nordisk", "COMP", "Offer", "Ablynx", "COMP"], ["Takeda Pharmaceutical", "COMP", "Plan_To", "Buy", "COMP"], ["Johnson & Johnson", "COMP", "Purchase", "Actelion", "COMP"], ["Gilead", "COMP", "Acquisition", "Kite", "COMP"], ["EY", "ORG", "Predict", "Significant_Rise", "ECON_INDICATOR"], ["Baker McKenzie", "ORG", "Predict", "Global_Healthcare_M&A", "SECTOR"], ["North America", "GPE", "Account_For", "Well_Over_Half", "ECON_INDICATOR"], ["Biotech_Firms", "COMP", "Discover", "Drugs_Of_Tomorrow", "CONCEPT"], ["Jesper Brandgaard", "PERSON", "Told", "Reuters", "ORG"], ["Ablynx", "COMP", "Example", "Strong_Technology_Development", "CONCEPT"], ["Large_Pharma_Companies", "COMP", "Some_Bureaucracy", "CONCEPT"], ["U.S.", "GPE", "Drug_Approvals", "21-year_high", "ECON_INDICATOR"], ["46_Novel_Medicines", "PRODUCT", "Win", "Green_Light", "CONCEPT"], ["Growing_Share", "ECON_INDICATOR", "Come", "Younger_Biotech_Companies", "COMP"], ["Large_Drugmakers", "COMP", "Experimental_Drugs", "Vital_Source", "CONCEPT"], ["In-house_Development_Pipelines", "COMP", "Top_Up", "CONCEPT"], ["Pricing_Pressures", "CONCEPT", "Push", "Companies", "COMP"], ["Niche_Disease_Areas", "CONCEPT", "Excel", "Biotech_Groups", "COMP"], ["U.S.", "GPE", "Tax_Changes", "Implementation", "CONCEPT"], ["Case_Equity_Partners", "COMP", "High_Hopes", "Drugs_Sector", "SECTOR"], ["U.S.", "GPE", "Companies", "Lots_Of_Cash", "CONCEPT"], ["Global_M&A_Market", "SECTOR", "Put_Capital_To_Work", "CONCEPT"], ["JP_Morgan_Healthcare_Conference", "ORG", "Start", "Monday", "DATE"], ["Biotech_Deals_And_Alliances", "COMP", "Often_Announced", "CONCEPT"]], "published": "2018-01-08T17:05:00.000+02:00"}